Oxford Asset Management’s Unity Biotechnology UBX Stock Holding History

Oxford Asset Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-21,904	Closed	-$1.58M	–	1237
2019 Q4	$1.58M	Buy	21,904 +2,543	+13%	+$179K	0.04%	566
2019 Q3	$1.18M	Buy	19,361 +10,551	+120%	+$746K	0.03%	846
2019 Q2	$837K	Buy	+8,810	New	+$750K	0.02%	1056
2019 Q1	–	Sell	-2,913	Closed	-$474K	–	1990
2018 Q4	$474K	Buy	+2,913	New	+$387K	0.01%	1215

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's UBX Position: Q1 2020 in Review

Oxford Asset Management sold out of Unity Biotechnology (UBX) in Q1 2020, closing a stake of 21,904 shares — an estimated $1.58M sold.

Oxford Asset Management first reported a position in UBX in Q4 2018 and held it in 4 quarters. The position peaked at $1.58M in Q4 2019. 74 funds tracked by Wall St. Rank hold UBX as of Q1 2020.

Oxford Asset Management reported no remaining Unity Biotechnology position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 21,904 Unity Biotechnology shares in Q1 2020, an estimated $1.58M.
Oxford Asset Management first reported a position in Unity Biotechnology in Q4 2018 and held it in 4 quarters.
Oxford Asset Management's Unity Biotechnology position peaked at $1.58M in Q4 2019.
74 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.